Registro:

Referencias:

• Non-Hodgkin Lymphoma, , http://www.leukemia-lymphoma.org
• Fisher, S.G., Fisher, R.I., The epidemiology of non-Hodgkin's lymphoma (2004) Oncogene, 23 (38), pp. 6524-6534. , DOI 10.1038/sj.onc.1207843
• Camby, I., Le, M.M., Lefranc, F., Kiss, R., Galectin-1: A small protein with major functions (2006) Glycobiology, 16 (11), pp. 137R-157R. , DOI 10.1093/glycob/cwl025
• He, J., Baum, L.G., Endothelial cell expression of galectin-1 induced by prostate cancer cells inhibits T-cell transendothelial migration (2006) Laboratory Investigation, 86 (6), pp. 578-590. , DOI 10.1038/labinvest.3700420, PII 3700420
• Van Der Leij, J., Van Den, B.A., Harms, G., Eschbach, H., Vos, H., Zwiers, P., Van Weeghel, R., Visser, L., Strongly enhanced IL-10 production using stable galectin-1 homodimers (2007) Molecular Immunology, 44 (4), pp. 506-513. , DOI 10.1016/j.molimm.2006.02.011, PII S016158900600037X
• Ilarregui, J.M., Croci, D.O., Bianco, G.A., Toscano, M.A., Salatino, M., Vermeulen, M.E., Geffner, J.R., Rabinovich, G.A., Tolerogenic signals delivered by dendritic cells to T cells through a galectin- 1-driven immunoregulatory circuit involving interleukin 27 and interleukin 10 (2009) Nat Immunol, 10, pp. 981-991
• Garin, M.I., Chu, N.-C., Golshayan, D., Cernuda-Morollon, E., Wait, R., Lechler, R.I., Galectin-1: A key effector of regulation mediated by CD4 +CD25+ T cells (2007) Blood, 109 (5), pp. 2058-2065. , http://bloodjournal.hematologylibrary.org/cgi/reprint/109/5/2058, DOI 10.1182/blood-2006-04-016451
• Toscano, M.A., Bianco, G.A., Ilarregui, J.M., Croci, D.O., Correale, J., Hernandez, J.D., Zwirner, N.W., Rabinovich, G.A., Differential glycosylation of TH1, TH2 and T H-17 effector cells selectively regulates susceptibility to cell death (2007) Nature Immunology, 8 (8), pp. 825-834. , DOI 10.1038/ni1482, PII NI1482
• Rubinstein, N., Alvarez, M., Zwirner, N.W., Toscano, M.A., Ilarregui, J.M., Bravo, A., Mordoh, J., Rabinovich, G.A., Targeted inhibition of galectin-1 gene expression in tumor cells results in heightened T cell-mediated rejection: A potential mechanism of tumor-immune privilege (2004) Cancer Cell, 5 (3), pp. 241-251. , DOI 10.1016/S1535-6108(04)00024-8, PII S1535610804000248
• Juszczynski, P., Ouyang, J., Monti, S., Rodig, S.J., Takeyama, K., Abramson, J., Chen, W., Shipp, M.A., The AP1-dependent secretion of galectin-1 by Reed-Sternberg cells fosters immune privilege in classical Hodgkin lymphoma (2007) Proceedings of the National Academy of Sciences of the United States of America, 104 (32), pp. 13134-13139. , http://www.pnas.org/cgi/reprint/104/32/13134, DOI 10.1073/pnas.0706017104
• Rodig, S.J., Ouyang, J., Juszczynski, P., Currie, T., Law, K., Neuberg, D.S., Rabinovich, G.A., Kutok, J.L., AP1-dependent galectin-1 expression delineates classical hodgkin and anaplastic large cell lymphomas from other lymphoid malignancies with shared molecular features (2008) Clin Cancer Res, 14, pp. 3338-3344
• Kuo, P.L., Hung, J.Y., Huang, S.K., Chou, S.H., Cheng, D.E., Jong, Y.J., Hung, C.H., Huang, M.S., Lung cancer-derived galectin-1 mediates dendritic cell anergy through inhibitor of DNA binding 3/IL-10 signaling pathway (2011) J Immunol, 186, pp. 1521-1530
• Banh, A., Zhang, J., Cao, H., Bouley, D.M., Kwok, S., Kong, C., Giaccia, A.J., Le, Q.T., Tumor galectin-1 mediates tumor growth and metastasis through regulation of T-cell apoptosis (2011) Cancer Res, 71, pp. 4423-4431
• Mathieu, V., Le, M.M., De Neve, N., Sauvage, S., Gras, T., Roland, I., Lefranc, F., Kiss, R., Galectin-1 knockdown increases sensitivity to temozolomide in a B16F10 mouse metastatic melanoma model (2007) Journal of Investigative Dermatology, 127 (10), pp. 2399-2410. , DOI 10.1038/sj.jid.5700869, PII 5700869
• Le Mercier, M., Lefranc, F., Mijatovic, T., Debeir, O., Haibe-Kains, B., Bontempi, G., Decaestecker, C., Mathieu, V., Evidence of galectin-1 involvement in glioma chemoresistance (2008) Toxicol Appl Pharmacol, 229, pp. 172-183
• Zacarias, F.M.F., Rico, M.J., Gervasoni, S.I., Ilarregui, J.M., Toscano, M.A., Rabinovich, G.A., Scharovsky, O.G., Low-dose cyclophosphamide modulates galectin-1 expression and function in an experimental rat lymphoma model (2007) Cancer Immunology, Immunotherapy, 56 (2), pp. 237-248. , DOI 10.1007/s00262-006-0176-0
• Mehrara, E., Forssell-Aronsson, E., Ahlman, H., Bernhardt, P., Specific growth rate versus doubling time for quantitative characterization of tumor growth rate (2007) Cancer Research, 67 (8), pp. 3970-3975. , DOI 10.1158/0008-5472.CAN-06-3822
• Furukawa, H., Iwata, R., Moriyama, N., Growth rate of pancreatic adenocarcinoma: Initial clinical experience (2001) Pancreas, 22 (4), pp. 366-369. , DOI 10.1097/00006676-200105000-00005
• Kuroishi, T., Tominaga, S., Morimoto, T., Tashiro, H., Itoh, S., Watanabe, H., Fukuda, M., Ogita, M., Tumor growth rate and prognosis of breast cancer mainly detected by mass screening (1990) Japanese Journal of Cancer Research, 81 (5), pp. 454-462
• Shackney, S.E., McCormack, G.W., Cuchural Jr., G.J., Growth rate patterns of solid tumors and their relation to responsiveness to therapy. An analytical review (1978) Annals of Internal Medicine, 89 (1), pp. 107-121
• Spratt, J.S., Spratt, T.L., Rates of growth of pulmonary metastases and host survival (1964) Ann Surg, 159, pp. 161-171
• Szereday, Z., Schally, A.V., Nagy, A., Plonowski, A., Bajo, A.M., Halmos, G., Szepeshazi, K., Groot, K., Effective treatment of experimental U-87MG human glioblastoma in nude mice with a targeted cytotoxic bombesin analogue, AN-215 (2002) Br J Cancer, 86, pp. 1322-1327
• Usuda, K., Saito, Y., Sagawa, M., Sato, M., Kanma, K., Takahashi, S., Endo, C., Fujimura, S., Tumor doubling time and prognostic assessment of patients with primary lung cancer (1994) Cancer, 74 (8), pp. 2239-2244. , DOI 10.1002/1097-0142(19941015)74:8<2239::AID-CNCR2820740806>3.0. CO;2-P
• Bajzer, Z., Gompertzian growth as a self-similar and allometric process (1999) Growth Dev Aging, 63, pp. 3-11
• Collins, V.P., Loeffler, R.K., Tivey, H., Observations on growth rates of human tumors (1956) Am J Roentgenol Radium Ther Nucl Med, 76, pp. 988-1000
• Scharovsky, O.G., Celoria, G.C., Racca, A.L., Font, M.T., Association between immune response and body conformation in the mouse (Mus musculus) (1991) Rev Brasil Genet, 14, pp. 373-380
• Tang, Q., Bluestone, J.A., The Foxp3+ regulatory T cell: A jack of all trades, master of regulation (2008) Nature Immunology, 9 (3), pp. 239-244. , DOI 10.1038/ni1572, PII NI1572
• Croci, D.O., Zacarias, F.M.F., Rico, M.J., Matar, P., Rabinovich, G.A., Scharovsky, O.G., Dynamic cross-talk between tumor and immune cells in orchestrating the immunosuppressive network at the tumor microenvironment (2007) Cancer Immunology, Immunotherapy, 56 (11), pp. 1687-1700. , DOI 10.1007/s00262-007-0343-y
• Demydenko, D., Berest, I., Expression of galectin-1 in malignant tumors (2009) Exp Oncol, 31, pp. 74-79
• Mather, K., The genetical structure of populations (1953) Symp Soc Exp Biol, 7, pp. 66-95
• Skibinski, D.O.F., Thoday, J.M., Disruptive selection with fixed optima (1979) Heredity, 42, pp. 327-335
• Rabinovich, G.A., Gabrilovich, D., Sotomayor, E.M., Immunosuppressive strategies that are mediated by tumor cells (2007) Annual Review of Immunology, 25, pp. 267-296. , DOI 10.1146/annurev.immunol.25.022106.141609
• Thijssen, V.L.J.L., Postel, R., Brandwijk, R.J.M.G.E., Dings, R.P.M., Nesmelova, I., Satijn, S., Verhofstad, N., Griffioen, A.W., Galectin-1 is essential in tumor angiogenesis and is a target for antiangiogenesis therapy (2006) Proceedings of the National Academy of Sciences of the United States of America, 103 (43), pp. 15975-15980. , DOI 10.1073/pnas.0603883103
• Tiemessen, M.M., Mitchell, T.J., Hendry, L., Whittaker, S.J., Taams, L.S., John, S., Lack of suppressive CD4 + CD25 + FOXP3 + T cells in advanced stages of primary cutaneous T-cell lymphoma (2006) J Invest Dermatol, 126, pp. 2217-22123
• Prabhala, R.H., Neri, P., Bae, J.E., Tassone, P., Shammas, M.A., Allam, C.K., Daley, J.F., Munshi, N.C., Dysfunctional T regulatory cells in multiple myeloma (2006) Blood, 107 (1), pp. 301-304. , http://www.bloodjournal.org/cgi/reprint/107/1/301, DOI 10.1182/blood-2005-08-3101
• Gandhi, M.K., Moll, G., Smith, C., Dua, U., Lambley, E., Ramuz, O., Gill, D., Khanna, R., Galectin-1 mediated suppression of Epstein-Barr virus-specific T-cell immunity in classic Hodgkin lymphoma (2007) Blood, 110 (4), pp. 1326-1329. , http://bloodjournal.hematologylibrary.org/cgi/reprint/110/4/1326, DOI 10.1182/blood-2007-01-066100
• Demers, M., Couillard, J., Giglia-Mari, G., Magnaldo, T., St-Pierre, Y., Increased galectin-7 gene expression in lymphoma cells is under the control of DNA methylation (2009) Biochem Biophys Res Commun, 387, pp. 425-429
• Demers, M., Biron-Pain, K., Hebert, J., Lamarre, A., Magnaldo, T., St-Pierre, Y., Galectin-7 in lymphoma: Elevated expression in human lymphoid malignancies and decreased lymphoma dissemination by antisense strategies in experimental model (2007) Cancer Research, 67 (6), pp. 2824-2829. , DOI 10.1158/0008-5472.CAN-06-3891
• St-Pierre, Y., Aoudjit, F., Lalancette, M., Potworowski, E.F., Dissemination of T cell lymphoma to target organs: A post-homing event implicating ICAM-1 and matrix metalloproteinases (1999) Leukemia and Lymphoma, 34 (1-2), pp. 53-61
• Matar, P., Rozados, V.R., Gonzalez, A.D., Dlugovitzky, D.G., Bonfil, R.D., Scharovsky, O.G., Mechanism of antimetastatic immunopotentiation by low-dose cyclophosphamide (2000) European Journal of Cancer, 36 (8), pp. 1060-1066. , DOI 10.1016/S0959-8049(00)00044-7, PII S0959804900000447
• Matar, P., Rozados, V.R., Gervasoni, S.I., Scharovsky, O.G., Down regulation of T-cell-derived IL-10 production by low-dose cyclophosphamide treatment in tumor-bearing rats restores in vitro normal lymphoproliferative response (2001) International Immunopharmacology, 1 (2), pp. 307-319. , DOI 10.1016/S1567-5769(00)00028-X, PII S156757690000028X
• Matar, P., Rozados, V.R., Gervasoni, S.I., Scharovsky, O.G., Th2/Th1 switch induced by a single low dose of cyclophosphamide in a rat metastatic lymphoma model (2001) Cancer Immunology, Immunotherapy, 50 (11), pp. 588-596. , DOI 10.1007/s00262-001-0237-3
• Blaser, C., Kaufmann, M., Muller, C., Zimmermann, C., Wells, V., Mallucci, L., Pircher, H., β-galactoside-binding protein secreted by activated T cells inhibits antigen-induced proliferation of T cells (1998) European Journal of Immunology, 28 (8), pp. 2311-2319. , DOI 10.1002/(SICI)1521-4141(199808)28:08<2311::AID-IMMU2311>3.0. CO;2-G
• Zuniga, E., Rabinovich, G.A., Iglesias, M.M., Gruppi, A., Regulated expression of galectin-1 during B-cell activation and implications for T-cell apoptosis (2001) Journal of Leukocyte Biology, 70 (1), pp. 73-79
• Saussez, S., Lorfevre, F., Lequeux, T., Laurent, G., Chantrain, G., Vertongen, F., Toubeau, G., Kiss, R., The determination of the levels of circulating galectin-1 and -3 in HNSCC patients could be used to monitor tumor progression and/or responses to therapy (2008) Oral Oncology, 44 (1), pp. 86-93. , DOI 10.1016/j.oraloncology.2006.12.014, PII S1368837507000140
• Saussez, S., Glinoer, D., Chantrain, G., Pattou, F., Carnaille, B., Andre, S., Gabius, H.-J., Laurent, G., Serum galectin-1 and galectin-3 levels in benign and malignant nodular thyroid disease (2008) Thyroid, 18 (7), pp. 705-712. , DOI 10.1089/thy.2007.0361
• Kamper, P., Ludvigsen, M., Bendix, K., Hamilton-Dutoit, S., Rabinovich, G.A., Møller, M.B., Nyengaard, J.R., D'Amore, F., Proteomic analysis identifies galectin-1 as a predictive biomarker for relapsed/refractory disease in classical Hodgkin lymphoma (2011) Blood, 117, pp. 6638-6664
• Le Mercier, M., Fortin, S., Mathieu, V., Kiss, R., Lefranc, F., Galectins and gliomas (2010) Brain Pathol, 20, pp. 17-27
• Verschuere, T., De Vleeschouwer, S., Lefranc, F., Kiss, R., Van Gool, S.W., Galectin-1 and immunotherapy for brain cancer (2011) Expert Rev Neurother, 11, pp. 533-543

Citas:

---------- APA ----------

---------- CHICAGO ----------

---------- MLA ----------

---------- VANCOUVER ----------